title: Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis.
authors.forename: Vaishali
authors.initials: V
authors.lastname: Sanchorawala
authors.forename: Kathleen T
authors.initials: KT
authors.lastname: Finn
authors.forename: Salli
authors.initials: S
authors.lastname: Fennessey
authors.forename: Anthony
authors.initials: A
authors.lastname: Shelton
authors.forename: Gheorghe
authors.initials: G
authors.lastname: Doros
authors.forename: Jerome B
authors.initials: JB
authors.lastname: Zeldis
authors.forename: David C
authors.initials: DC
authors.lastname: Seldin
mesh_terms: D000686:Amyloidosis / Q000097:blood / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D018572:Disease-Free Survival; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000097:blood; D000077269:Lenalidomide; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D005938:Glucocorticoids; D007147:Immunoglobulin Light Chains; D013792:Thalidomide; D003907:Dexamethasone; D000077269:Lenalidomide